The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer.

MLA

Chen, Siyi, et al. “The Longitudinal Changes in Multiparametric MRI during Neoadjuvant Chemotherapy Can Predict Treatment Response Early in Patients with HER2-Positive Breast Cancer.” European Journal of Radiology, vol. 178, Sept. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejrad.2024.111656.

APA

Chen, S., Zheng, B., Tang, W., Ding, S., Sui, Y., Yu, X., Zhong, Z., Kong, Q., Liu, W., & Guo, Y. (2024). The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer. European Journal of Radiology, 178, N.PAG. https://doi.org/10.1016/j.ejrad.2024.111656

Chicago

Chen, Siyi, Bingjie Zheng, Wenjie Tang, Shishen Ding, Yi Sui, Xiaomeng Yu, Zhidan Zhong, Qingcong Kong, Weifeng Liu, and Yuan Guo. 2024. “The Longitudinal Changes in Multiparametric MRI during Neoadjuvant Chemotherapy Can Predict Treatment Response Early in Patients with HER2-Positive Breast Cancer.” European Journal of Radiology 178 (September): N.PAG. doi:10.1016/j.ejrad.2024.111656.